Projects per year
Personal profile
Headline
ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology ASSISTANT PROFESSOR | Oncological Sciences
Fingerprint
Dive into the research topics where Lewis Silverman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
MPN Research Consortium
Hoffman, R. R., Dueck, A. A. C., Migliaccio, A. R. A. F., Dueck, A. C., Goldberg, J. D., Hoffman, R., Mascarenhas, J., Goldberg, J. J. D., Levine, R. L., Mascarenhas, J., Migliaccio, A. R. R., Migliaccio, A. R., Pahl, H. L., Prchal, J. T., Rampal, R., Weinberg, R. R. S., Rampal, R. R., Levine, R. R. L., Silverman, L., Spivak, J. L., Weinberg, R. S. & Hoffman, R. R.
1/07/06 → 28/02/23
Project: Research
-
-
CLINICAL TRIAL: ON 01910NA IN PATIENTS WITH REFRACTORY LUKEMIA OR MYELODYSPLAST
National Center for Research Resources
1/03/09 → 31/07/09
Project: Research
-
-
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Zeidan, A. M., Boss, I., Beach, C. L., Copeland, W. B., Thompson, E., Fox, B. A., Hasle, V. E., Ogasawara, K., Cavenagh, J., Silverman, L. R., Voso, M. T., Hellmann, A., Tormo, M., O’Connor, T., Previtali, A., Rose, S. & Garcia-Manero, G., 12 Apr 2022, In: Blood advances. 6, 7, p. 2207-2218 12 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Zeidan, A. M., Boss, I., Beach, C. L., Copeland, W. B., Thompson, E., Fox, B. A., Hasle, V. E., Hellmann, A., Taussig, D. C., Tormo, M., Voso, M. T., Cavenagh, J., O’Connor, T., Previtali, A., Rose, S. & Silverman, L. R., 12 Apr 2022, In: Blood advances. 6, 7, p. 2219-2229 11 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine
Feld, J., Tremblay, D., Navada, S. C. & Silverman, L. R., 2022, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Review article › peer-review
-
Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factor–Mutant Neoplasms
Wheeler, E. C., Vora, S., Mayer, D., Kotini, A. G., Olszewska, M., Park, S. S., Guccione, E., Teruya-Feldstein, J., Silverman, L., Sunahara, R. K., Yeo, G. W. & Papapetrou, E. P., 1 Mar 2022, In: Cancer Discovery. 12, 3, p. 836-855 20 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases
Feld, J., Silverman, L. R. & Navada, S. C., Apr 2021, In: Clinical Lymphoma, Myeloma and Leukemia. 21, 4, p. e415-e422Research output: Contribution to journal › Review article › peer-review
2 Scopus citations
Press / Media
-
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101
27/06/22
1 item of Media coverage
Press/Media
-
Transfusion Dependence and Transfusion Support in MDS Webinar
24/04/21
1 item of Media coverage
Press/Media
-
Onconova Therapeutics Publicizes Journal of Phase 1 Fallouts
8/07/20
1 item of Media coverage
Press/Media